Adicet Bio, Inc.
0.7505-0.11 (-12.3%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · ACET · USD
Key Stats
Market Cap
115.02MP/E (TTM)
-Basic EPS (TTM)
-1.30Dividend Yield
0%Recent Filings
8-K
Nasdaq listing transfer granted
Adicet Bio's common stock will transfer from the Nasdaq Global Market to the Nasdaq Capital Market effective October 9, 2025, after Nasdaq granted a 180-day extension until April 6, 2026, to meet the $1.00 minimum bid price rule. The company, previously notified of noncompliance on April 7, 2025, plans to monitor its stock price closely and may pursue a reverse stock split if needed. No immediate delisting effects apply. Success isn't guaranteed amid ongoing risks.
8-K
ADI-001 lupus data shines
Adicet Bio unveiled promising preliminary Phase 1 data for ADI-001 on October 7, 2025, showing all seven lupus patients (five with nephritis, two systemic) achieved rapid SLEDAI-2K reductions and discontinued immunosuppressants after a single dose. In lupus nephritis cases, 100% hit renal responses, including three complete ones with DORIS remissions, while the therapy proved well-tolerated with no serious adverse events or ICANS. This immune reset hints at durable benefits. Yet early data demands larger trials.
8-K
Adicet Bio launches $80M stock offering
Adicet Bio entered an underwriting agreement on October 7, 2025, for a registered direct offering of 70 million common shares at $1.00 each and pre-funded warrants to purchase 10 million shares at $0.9999 per underlying share, expecting to close October 8 with net proceeds of $74.8 million after fees. This capital raise bolsters the biotech's runway amid clinical development. Yet risks loom from market volatility. Completion hinges on standard closing conditions.
8-K
Adicet Q2 loss widens slightly
Adicet Bio reported Q2 2025 net loss of $31.2 million, up slightly from $29.9 million last year, with R&D expenses rising to $28.4 million amid ongoing ADI-001 autoimmune trials. The company dosed its first systemic sclerosis patient and expanded enrollment to new indications like IIM and AAV, while prioritizing ADI-212 for prostate cancer and discontinuing ADI-270. Cash stands at $125 million, extending runway to Q4 2026. Pipeline focus sharpens resources.
10-Q
Q2 2025 results
Adicet Bio, Inc. reported a net loss of $31.2 million for Q2 2025, up 4% from $29.9 million in Q2 2024, driven by higher R&D expenses of $28.4 million (up 10%) offset by lower G&A costs of $4.0 million (down 43%). Cash reserves stood at $125.0 million, supporting operations into Q4 2026. The company advanced ADI-001 in autoimmune trials, dosing the first SSc patient and planning data readout in H2 2025, while discontinuing ADI-270 to focus on ADI-001 and ADI-212. A 30% workforce reduction was announced to extend runway. Nasdaq compliance remains a concern with a $1.00 bid price requirement deadline in October 2025.
ADAG
Adagene Inc.
1.84+0.04
ADAP
Adaptimmune Therapeutics plc
0.05+0.00
ADCT
ADC Therapeutics SA
4.61+0.18
ADPT
Adaptive Biotechnologies Corpor
16.80-0.10
ADTX
Aditxt, Inc.
0.11-0.02
ALLO
Allogene Therapeutics, Inc.
1.22-0.04
APLT
Applied Therapeutics, Inc.
1.22-0.08
CLLS
Cellectis S.A.
3.63+0.05
INAB
IN8bio, Inc.
2.00-0.10
QTTB
Q32 Bio Inc.
2.68+0.12